Lausanne, November 26, 2024 - Leman Biotech, a clinical-stage biotechnology company specializing in the development, production, and commercialization of innovative metabolic immunotherapies, has been selected for an oral presentation at the ESMO Immuno-Oncology Congress 2024.
The ESMO Immuno-Oncology Congress, organized by the European Society for Medical Oncology (ESMO), is a prestigious international event that highlights recent scientific advancements, challenges, and emerging trends in the rapidly evolving field of immuno-oncology. This year, the congress will take place from December 11–13, 2024, in Geneva, Switzerland.
At the congress, Leman Biotech will present clinical results from its investigator-initiated trials of metabolically armed CD19 CAR-T cell therapy for relapsed or refractory B-cell hematological malignancies. The co-founder and chair of Leman Biotech, Prof. Li Tang, who also serves as an associate professor at EPFL, will deliver the presentation.
Details of the oral presentation:
Session: Proffered Paper session
LBA1: lL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and lmprove Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
Presentation Time: Wednesday, December 11, 2024 16:15 - 16:25
Session Time: Wednesday, December 11, 2024 16:15 - 18:00
Location: Room B, the Palexpo exhibition centre
Link: https://cslide.ctimeetingtech.com/coasis_21066/attendee/confcal/show/session/7
Meta 10 Technology
Leman Biotech's Metabolic Reprogramming Technology (Meta 10) represents an innovative approach to combating T-cell exhaustion. Preclinical studies have demonstrated its ability to activate oxidative phosphorylation metabolism in terminally exhausted T cells, restoring their proliferative potential and cytotoxic activity. Promising results from these studies include effective tumor clearance in various mouse models and the induction of stem-like immune memory cells.
In early 2023, Leman Biotech initiated an investigator-initiated clinical trial (IIT) for metabolically armed CD19 CAR-T therapy (Meta10-19 CAR-T) targeting patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) and acute B-lymphoblastic leukemia (r/r B-ALL). Remarkably, all patients treated with Meta10-19 CAR-T have achieved complete responses at low doses with minimal side effects. These findings highlight the immense clinical potential of Meta 10 technology.
About Leman Biotech
Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, a leader in AI-driven drug research and development. The company integrates innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies.
Leman Biotech's core technology, Meta 10, has shown the potential to cure solid tumors, as evidenced by published research in leading academic journals, including Nature Immunology and Nature Biotechnology. The platform is also protected by PCT patents covering major global markets.
The company recently completed a successful angel-plus financing round, raising nearly $18 million, and has plans for further fundraising. Committed to addressing the key challenges in cancer immunotherapy, Leman Biotech aims to improve response rates and efficacy, working tirelessly toward the ultimate goal of curing cancer.
